$SONN Sonnet BioTherapeutics Announces the Completion of a Successful Non-Human Primate Study of SON-1010
Mon, November 30, 2020, 6:30 AM MST
Compared to recombinant human IL-12, SON-1010 demonstrated an enhanced pharmacokinetic (PK) profile that was similar to IgG antibodies
SON-1010 continues to be well tolerated at doses far exceeding levels expected in potential future clinical trials, without producing detectable cytokine imbalances
Analysis of Interferon-? levels, a key biomarker of antitumor activity, suggest potent on-target pharmacodynamic (PD) effects